Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX vs Oxaliplatin + 5-FU CI in Advanced Colorectal Cancer
NCT00202774Phase 3Completed
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Apr 2002
- Primary completion
- Aug 2004
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine in colorectal cancer (CRC) (2 arms), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoint: Time to Disease Progression. Started Apr 2002; status: completed.
02
Drugs
capecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00202774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00202774.